Evaluation of the Omnipod DASH in Children and Adolescents With Type 1 Diabetes Mellitus
NCT ID: NCT05377385
Last Updated: 2022-09-23
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
36 participants
OBSERVATIONAL
2022-04-13
2022-09-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Hypoglycemia at Initiation of Pump Therapy in Children With Type 1 Diabetes
NCT01840358
Effectiveness and Safety Study of the DexCom™ G4 Continuous Glucose Monitoring System in Children and Adolescents With Type 1 Diabetes Mellitus
NCT01185496
Psychosocial Issues in Insulin Pump Therapy in Children With Type 1 Diabetes Mellitus (DM)
NCT01338922
Assessing the Impact of Control-IQ Technology
NCT04838561
Comparison of Insulin Detemir and Insulin Semilente®MC in Type 1 Diabetes
NCT00184639
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The metabolic control is studied retrospectively from data extracted from the medical records, i.e. the results of the determination of HbA1c and the results from continuous glucose monitoring (CGM) at the start, and after 2, 4 and 6 months of the wearing of the Omnipod DASH insulin pump.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
OTHER
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Study group
Children and adolescents with type 1 diabetes mellitus who started in 2021 in the Jessa Hospital with the Omnipod DASH insulin administration device.
Questionnaire
Questionnaire about usability of the Omnipod DASH insulin administration system
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Questionnaire
Questionnaire about usability of the Omnipod DASH insulin administration system
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients who started in 2021 with the Omnipod DASH insulin administration system in the Jessa Hospital
Exclusion Criteria
* Children and adolescents with type 1 diabetes treated with insulin pens or other insulin pumps
6 Years
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Jessa Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Guy Massa
Role: PRINCIPAL_INVESTIGATOR
Jessa Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Jessa Hospital
Hasselt, Limburg, Belgium
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2022/018
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.